Michael Ingram, MD
Psychiatry · Bay City, MINPI 1295767283
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $191,827 of the $255,285 with a category attached, or 75.1%. 24 manufacturers reported payments, led by Johnson & Johnson at 36.0% of the total. Among psychiatry clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 491 payments — averaging $519.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$92K
- Alkermes, Inc.$73K
- Otsuka America Pharmaceutical, Inc.$34K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$26K
- Teva Pharmaceuticals USA, Inc.$21K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$8K
- plus $2K from 18 others
What the payments were for
- Consulting fees$21,6408%
- Speaking & faculty fees$191,82775%
- Travel & lodging$29,28411%
- Food & beverage$12,4955%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 133 | $91,893 |
| Alkermes, Inc. | 103 | $73,024 |
| Otsuka America Pharmaceutical, Inc. | 80 | $33,941 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 36 | $25,642 |
| Teva Pharmaceuticals USA, Inc. | 37 | $21,332 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 12 | $7,539 |
| Neurocrine Biosciences, Inc. | 23 | $359 |
| Validus Pharmaceuticals LLC | 3 | $346 |
| Lundbeck LLC | 15 | $255 |
| AbbVie | 10 | $206 |
| Sunovion Pharmaceuticals Inc. | 10 | $151 |
| Axsome Therapeutics, Inc. | 7 | $131 |
| Indivior Inc. | 4 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $91 |
| Sage Therapeutics, LLC | 2 | $88 |
| Acadia Pharmaceuticals Inc | 1 | $53 |
| USWM, LLC | 2 | $28 |
| Antares Pharma, Inc. | 1 | $18 |
| Corium, LLC | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Tris Pharma Inc | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$199,615
- LYBALVI$96,031
- INVEGA SUSTENNA$80,850
- INVEGA TRINZA$80,001
- ARISTADA INITIO$40,494
- CAPLYTA$24,871
- ABILIFY MAINTENA$19,918
- AUSTEDO$19,050
- REXULTI$17,501
- SPRAVATO$9,020
- ABILIFY ASIMTUFII$6,298
- Austedo XR$990
- UZEDY$840
- Equetro$313
How this compares
$255,285 in reported general payments places this provider in the 95th percentile of 1,166 psychiatry providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 52 | $321,555 |
| IngrezzaValbenazine Tosylate | 14 | $156,964 |
| Austedo XrDeutetrabenazine | 24 | $114,964 |
| VraylarCariprazine Hcl | 58 | $86,789 |
| RexultiBrexpiprazole | 34 | $72,556 |
| TrintellixVortioxetine Hydrobromide | 46 | $38,577 |
| AuvelityDextromethorphan Hbr/Bupropion | 18 | $26,036 |
| EmsamSelegiline | 11 | $22,965 |
| SpravatoEsketamine Hcl | 11 | $18,155 |
| Paliperidone ErPaliperidone | 45 | $7,700 |
| Asenapine Maleate | 35 | $5,223 |
| Clozapine | 35 | $4,731 |
| Duloxetine Hcl | 122 | $3,678 |
| Trazodone Hcl | 214 | $3,446 |
| Buspirone Hcl | 196 | $3,323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $21,332 | $436,51976 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $359 | $156,96414 claims |
| AbbVieVraylar | $206 | $86,78958 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $33,941 | $72,55634 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $91 | $38,57746 claims |
| Axsome Therapeutics, Inc.Auvelity | $131 | $26,03618 claims |
| Johnson & JohnsonSpravato | $91,893 | $18,15511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,166 psychiatry providers in Michigan.
Other psychiatry in Bay City
- Andreas SidiropoulasDetroit$2.8M
- Welton WashingtonYpsilanti$1.4M
- Joel YoungRochester Hills$1.1M
- Manzar RajputMonroe$612K
- William GuySouthfield$562K
- Robert LagrouClarkston$267K
- Samuel WedesLivonia$158K
- Arash JavanbakhtDetroit$102K
- Theodore RuzaWest Bloomfield$100K
- Kameswara TatineniBattle Creek$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.